Bone mineral density in the inflammatory bowel disease study population
| Patient characteristic | |
|---|---|
| *Values are mean (SD) [range]. | |
| OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor kappa B; sRANKL, soluble receptor activator of nuclear factor kappa B; BMD, bone mineral density. | |
| n | 43 |
| Crohn’s disease (n) | 29 |
| Ulcerative colitis (n) | 14 |
| Age (y)* | 33.14 (1.12) [19.2–59.2] |
| Disease duration (y)* | 3.4 (5.7) [0.2–23.7] |
| Time (y) between OPG/sRANKL measurement and BMD assessment* | 0.4 (0.4) [0.0–1.1] |
| OPG (pg/ml)* | 1986.13 (751.53) [963.06–3983.19] |
| sRANKL (pg/ml)* | 7.83 (4.51) [2.9–28.2] |
| OPG/sRANKL* | 292.44 (21.35) [110.69–632.77] |
| BMD (g/cm2) lumbar vertebrae | 0.912 (0.15) |
| T score (L1–L4) | −1.4 (1.48) |
| Z score (L1–L4) | −1.25 (1.46) |
| BMD (g/cm2) femoral neck | 0.713 (0.12) |
| T score (femoral neck) | −1.5 (1.13) |
| Z score (femoral neck) | −1.2 (1.17) |